Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade · PMID 42321916
View analysis →A grade · PMID 42372741
View analysis →A grade · PMID 42382416
View analysis →A grade · PMID 42150584
View analysis →This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 86.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 96.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 86.6/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 48.2; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 86.6/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 78.1; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 86.5/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 95.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 86.5/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 94.9; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 86.2/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 86.1; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 86.1/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 68.2; sample size: 90.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 86.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 60.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.8/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 54.2; sample size: 50.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.8/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 84.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.7/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 81.1; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 48.1; sample size: 90.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 83.1; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 58.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.4/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 62.2; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.4/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 62.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 89.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.1/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 85.7; sample size: 60.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.1/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 45.5; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.0/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 40.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
